Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million. As part of the deal, the…

New research from the Human Microbiology Institute has shown that many diseases, from Alzheimer’s to cancer and others, could be linked to bacterial viruses, a…

Shares in tiny Galectin Therapeutics fell 50% in after-hours trading on the back of data from a Phase IIa nonalcoholic steatohepatitis trial.

GlaxoSmithKline has found a buyer for a French drug discovery site rendered redundant by its revamped dual-hub R&D model.

Shire has returned rights to the two biosimilars that Baxalta had in development.

The Cambridge, MA-based company is ready to graduate from a venture-oriented CEO to a former pharma exec ready to jump into the clinical fray.

BMS has partnered with Nektar Therapeutics in a clinical collaboration that aims to boost the efficacy of Opdivo with Nektar candidate NKTR-214.

Amgen’s Kyprolis has come up short against Takeda’s Velcade in a Phase III trial in patients newly diagnosed with multiple myeloma.